Survey data showed that most women reported pain relief (61–95,5%), prospective cohort studies and an RCT with PEA combination agents showed significant pain reduction (average 3,35±1,39 on a 10-point scale after 3 months), but one RCT showed no pain reduction and heterogeneous formulations/dosages limit definitive statements.
Systematic review on medical cannabis for gynecological pain syndromes (chronic pelvic pain, vulvodynia, endometriosis, interstitial cystitis, malignancies); k=16 studies (6 prospective cohort studies, 1 RCT on palmitoylethanolamide-PEA combinations, survey data). Cannabis prevalence 13–27%; 61–95,5% of users reported pain reduction. Prospective studies on PEA combinations showed an average VAS reduction of 3,35±1,39 points after 3 months (p<0.05). THC dosages up to 70mg, CBD up to 2.000mg; primary route of administration inhalational/oral, several times weekly. One RCT on a fatty acid amide enzyme inhibitor showed no pain reduction.
The highest of four GRADE levels, the effect estimate is very reliable.
The impediment to action advances action.